Rhythm Pharma Rises on Unconfirmed $150-a-Share Takeover Proposal from Eli Lilly
Rhythm Pharma shares climbed on reports of a $150 bid from Eli Lilly, including a contingent value right, following AstraZeneca’s $124 offer.
Already have an account? Sign in.